跳至主要内容
临床试验/CTIS2023-510041-16-00
CTIS2023-510041-16-00进行中(未招募)1 期

Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma - GITS

Region Vaesterbotten0 个研究点目标入组 240 人开始时间: 2024年5月6日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Newly diagnosed open-angle glaucoma (incl. normal pressure glaucoma) or PEX glaucoma in one or both eyes (both eyes can be included as study eyes if they fulfill the criteria of inclusion/exclusion)., VFI (Visual Field Index)=65%, applicable for both eyes even if only one eye will be included., Patient should be previously untreated with intraocular pressure lowering medication., Age: 40-78 years at time of inclusion.

排除标准

  • Pregnant or breast feeding women or women in childbearing potential not using acceptable contraceptive method., Patients with contraindications to the glaucoma medicine to be given., If there is any obstacle for performing the LTP., Disease or condition that probably prohibits long-term follow-up., Intraocular surgery except uncomplicated cataract operation., Diabetes with proliferative retionopathy or serious non-proliferative retionopathy [(intra-retinal bleedings, pronounced intra-retinal microvasculation, definite venous beading macular edema with hard exudates that reach fovea according to International Clinical Diabetic Retionopathy and Macular Edema Disease Severity scales (Wilkinson et al 2003)]., Neurological and other non-glaucoma conditions, except cataract, that can affect the vision.

研究者

发起方
Region Vaesterbotten

相似试验